Navigation Links
Silence Therapeutics Announces Successful Opposition of Glover Patent
Date:7/11/2008

LONDON, July 11 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN), a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety.

The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule.

Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc., Sirna Therapeutics, and Nucleonics, Inc. In the course of the oral hearing which lasted from July 08 to July 10, 2008, Cancer Research Technology Ltd. filed a total of seven auxiliary requests so as to defend the patent in a limited manner. None of these requests was able to overcome the concerns of the Opposition Division that the patent was legally invalid. Cancer Research Technology and Alnylam are expected to appeal the decision.

Jeff Vick, Chief Executive Officer of Silence Therapeutics, said, "The Glover patent was arguably Alnylam's broadest patent and the successful opposition represents an important victory for us in allowing us to maintain our Freedom to Operate. We have long believed that this patent would be revoked and are very pleased with the outcome. This decision by the European Patent Office further strengthens our leading position in the field of RNA interference."

Notes to Editors:

About Silence Therapeutics plc (http://www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading European RNAi focused bio
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
5. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
6. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
11. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... IAC Industries wants to share with you ... needing to set up and furnish a research lab knowing ... within a year’s time. How does a company make choices ... temporary? What is efficient and cost-effective? , The solution ... Industries. The planners at DisperSol determined that the concept of ...
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of Palm Clinic ... about Appearance Medicine . Although Dr. Hart regularly teaches ... to lecture in China, and quite a different experience it ... 12 and 7 million people respectively. Interest in cosmetic facial ... in time. As Dr. Hart passed through the Fuzhou airport ...
(Date:5/16/2013)... 2013  The registration deadline has been extended until ... 2013 National Conference, the premier conference for bioscience financial ... the Hilton San Diego Bayfront. "We ... and want to make sure as many people as ... Brandi Roberts , Chief Financial Officer of Mast ...
Breaking Biology Technology:Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4
... Oct. 31 Novo Nordisk (NYSE:,NVO), a global healthcare company, today ... 30, 2007. -- Novo Nordisk increased sales by 14% in ... kroner due to a significant negative currency development. ... Danish kroner). -- Sales of NovoSeven(R) increased ...
... Kinetics Study ... Data, ... OTC: MGIFF), a clinical-stage developer of drugs for infectious,diseases will present at ... the New York Palace Hotel in New York,NY on November 5-7, 2007. ...
... (Nasdaq: IDIX ) announced today that it will ... on Tuesday, November 6,2007 after the U.S. financial markets ... press release, Idenix,management will host a conference call at ... the company,s financial results for the third quarter,2007. ...
Cached Biology Technology:Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin 2MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... 95th Annual Meeting in San Francisco, CA from ... promote the entry of students, postdoctorates and scientists ... basic science community and to encourage the participation ... Meeting. , Awards are given to poster/platform presenters ...
(Date:5/16/2013)... scientists have used ancient shorelines to predict the stability of ... a high shoreline from three million years ago, for example ... were thought to be evidence of a high sea level ... has led many scientists to think that if the world,s ... do just the same in our modern, progressively warming world. ...
(Date:5/16/2013)... cellular layer lining the body,s blood vessels, is ... in thickness, this super-tenuous structure routinely withstands blood ... create a unique and highly dynamic barrier that ... the body,s circulatory system. , It,s also extremely ... physically breached to enable immune cells to ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... the Marine Biological,Laboratory (MBL) has published the ... supports her hypothesis that, when combined, the ... BCE--can act synergistically to alter a key ... previously studied the effects,of these pollutants individually, ...
... of fluorescence detection developed by researchers at Baylor College ... doors that would take DNA sequencing to the patient's ... a crime or a battlefield. , "We could eventually ... DNA" without manipulation now performed in the laboratory, said ...
... The crystallized form of a molecular machine that can ... paths for treating diseases such as some forms of ... Purdue University researchers froze one of these molecular machines, ... intron, at mid-point in its work cycle. When frozen, ...
Cached Biology News:Study identifies predictors of HIV drug resistance in patients beginning triple therapy 2Study identifies predictors of HIV drug resistance in patients beginning triple therapy 3Color-blind method opens new doors in DNA sequencing 2Color-blind method opens new doors in DNA sequencing 3Molecular machine may lead to new drugs to combat human diseases 2Molecular machine may lead to new drugs to combat human diseases 3
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
... SSCP kit provides all the accessories necessary ... single-stranded conformation polymorphism analysis (SSCP) with the ... includes a cooling finger adaptor for use ... sets of 20 cm plates, 2 sets ...
... analysis kit for 25 chips provides the ... RNA analysis (at nanogram levels) with the ... 25 RNA StdSens microfluidic chips, 2 x ... microliters RNA StdSens stain, 2 x 20 ...
... has made microcapillary flow cytometry accessible to ... alike will appreciate the latest addition to ... to use, surprising affordable, and very compact ... includes such features as absolute cell counts, ...
Biology Products: